Anti-sclerostin antibodies

Details Anti-sclerostin antibodies Anti-sclerostin antibodies

2008-03-11

2010-06-29

Kemmerer, Elizabeth C. (Department: 1646)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S133100, C424S134100, C424S139100, C424S145100, C424S158100, C530S387100, C530S387300, C530S387900, C530S388100, C530S388150, C530S388230, C530S388240, C530S389100, C530S389200

Reexamination Certificate

active

07744874

ABSTRACT:
Humanized and chimeric antibodies are provided that specifically bind human sclerostin and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful for increasing bone mass, bone mineral density and bone strength and for the treatment of various disorders, e.g., osteoporosis, in human subject.

REFERENCES:
patent: 6395511 (2002-05-01), Brunkow et al.
patent: 6489445 (2002-12-01), Brunkow et al.
patent: 6495736 (2002-12-01), Brunkow et al.
patent: 6803453 (2004-10-01), Brunkow et al.
patent: 7192583 (2007-03-01), Brunkow et al.
patent: 2005/0106683 (2005-05-01), Winkler et al.
patent: 1 133 558 (2006-08-01), None
patent: WO 00/32773 (2000-06-01), None
patent: WO 01/98491 (2001-12-01), None
patent: WO 03/106657 (2003-12-01), None
patent: WO 2003/106657 (2003-12-01), None
patent: WO 2005/003158 (2005-01-01), None
patent: WO 2005/014650 (2005-02-01), None
patent: WO 06/119107 (2006-11-01), None
patent: WO 2006/119062 (2006-11-01), None
patent: WO 2006/119107 (2006-11-01), None
patent: WO 2008/061013 (2008-05-01), None
Lewiecki et al. (2009, Expert Opinion Emerging Drug 14:129-144).
Eddleston et al. (2009, J. Bone Min. Res. 24:1662-1671).
Li et al. (2009, J. Bone Min. Res. 24:578-588).
Bladé et al. (2008, Curr. Opin. Oncol. 20:697-704).
Balint, R., et al., “Antibody Engineering by Parsimonious Mutagenesis,”Gene 137(1):109-118 (1993).
Alves, et al.,Rev. Bras. Genet.4:825-834 (1982).
Balemans, et al,Human Mol. Genetics10(5):537-543 (2001).
Beighton, et al.,Clinical Genetics, 25:175-181 (1984).
Brunkow, et al.,Am. J. Hum. Genet.68: 577-589 (2001).
Uitterlinden, et al.,Am. J. Hum. Genet.75:1032-1045 (2004).
Van Hul, et al.,Am. J. Hum. Genet.2:391-399 (1998).
Winkler, et al.,The EMBO Journal22(23):6267-6275 (2003).
Linear human genomic DNA from chromosome 17, EMBL Accession No: AC003098 (Nov. 14, 1997).
Linear mRNA, human EST, EMBL Accession No. AA393939 (May 19, 1997).
Linear mRNA, human EST, EMBL Accession No: AI113131 (Sep. 4, 1998).
International Preliminary Report on Patentability issued by the International Bureau of WIPO, Sep. 22, 2009.

Affiliated with

Also associated with

Rating

Anti-sclerostin antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-sclerostin antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-sclerostin antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4240191